| 冯 蕾,裴瑞霞,李兴波,李小莉,王艳芳.四妙散加味和秋水仙碱治疗湿热蕴结型痛风的疗效观察[J].现代生物医学进展英文版,2017,17(25):4912-4915. |
| 四妙散加味和秋水仙碱治疗湿热蕴结型痛风的疗效观察 |
| Clinical Effect of Modified Simiao San Compared and Colchicine in the Treatment of Damp Heat Gout |
| Received:November 23, 2016 Revised:December 20, 2016 |
| DOI：10.13241/j.cnki.pmb.2017.25.027 |
| 中文关键词: 湿热蕴结型痛风 四妙散加味 秋水仙碱 生活质量 |
| 英文关键词: Damp Heat Gout Modified Simiao San Colchicine Life quality |
| 基金项目: |
|
| Hits: 357 |
| Download times: 214 |
| 中文摘要: |
| 摘要 目的：探讨四妙散加味与秋水仙碱治疗湿热蕴结型痛风的临床疗效和安全性。方法：收集2015年内我院收治的湿热蕴结型痛风患者120例作为研究对象，采用随机数字表法将其分为A组、B组及C组，每组各包含患者40例。A患者采用四妙散加味治疗，B组患者采用秋水仙碱治疗，C组患者采用四妙散加味联合秋水仙碱治疗。对三组的治疗效果、症状得分、治疗前后炎性因子水平及其他生化指标、不良反应及复发情况进行检测与比较。结果：A组总有效率及总显效率分别为92.5%及57.5%，C组为95.0%及65.0%，均显著高于B组的77.5%及35.0%，差异有统计学意义(P<0.05)。三组治疗后症状得分均显著低于治疗前，实验室指标均较治疗前明显改善，差异显著(P<0.05)。其中，C组血沉(ESR)及血尿酸水平(UA)变化幅度最大，较其他两组比较有显著差异(P<0.05)。A组及C组不良反应发生率分别为5.0%及7.5%，显著低于B组的22.5%，差异有统计学意义(P<0.05)。C组SF-36评分明显低于A组及B组，差异有统计学意义(P<0.05)。结论：四妙散加味联合秋水仙碱治疗湿热蕴结型痛风对比任何一种单药治疗疗效更佳，显著改善患者的生活质量，安全性更高。 |
| 英文摘要: |
| ABSTRACT Objective: To compare the clinical effect and safety of modified Simiao San and colchicines on the damp heat gout. Methods: 120 patients with damp heat gout admitted in our hospital in 2015 were selected and randomly divided into group A, group B and group C with 40 cases in each group. Patients in group A were given modified Simiao San, patients in group B were given colchicine, patients in group C were given modified Simiao San combined with colchicine. Then the clinical effect, scores of symptoms, expression levels of inflammatory factors and other biochemical indexes, adverse reactions and recurrence rate of 3 groups were compared berween three groups. Results: The total effective rate and effectually effective rate of group A were 92.5% and 57.5% respectively, which were 95.0% and 65.0% in group C was, obviously higher than 77.5% and 35.0% of group B(P<0.05). The symptom scores of 3 groups after treatment were all lower than those before treatment(P<0.05). The variety of ESR and UA of group C were greater than other groups (P<0.05). The incidence rate of adverse reaction in group A and group C were 5.0% and 7.5% respectively, obviously lower than 22.5 of group B with statistically signficance (P<0.05). The SF-36 score of group C was obviously lower than those of group A and group B with statistically significance (P<0.05). Conclusion: Modified Simiao San combined with colchicine had better effect and safety compared to single medicine, which could greatly improve the quality of life. |
|
View Full Text
View/Add Comment Download reader |
| Close |
